LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 16, 2015--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster
presentations related to studies with ganetespib, a novel, potent small
molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3
development, and STA-12-8666, the company’s leading candidate from its
proprietary Hsp90 inhibitor Drug Conjugate (HDC) Program, will be
presented at the 2015 Annual Meeting of the American Association of
Cancer Research (AACR) in Philadelphia, Pennsylvania.
“Preclinical data presented at this year’s AACR meeting add to the body
of data supporting the potential benefit of combining ganetespib with
multiple therapeutic modalities in the treatment of various cancers,
including non-small cell lung cancer. These data continue to provide
support for our broad clinical strategy, including the ongoing Phase 3
GALAXY-2 trial and our large, randomized, investigator-sponsored
studies, and will help shape our future clinical direction,” said Anne
Whitaker, President and Chief Executive Officer of Synta. “In addition,
we continue to see highly encouraging preclinical proof of concept data
for our lead HDC candidate, STA-12-8666, in several animal models,
including resistant pancreatic cancer and small cell lung cancer patient
derived xenografts. We are encouraged by the progress of this program
and look forward to moving toward an IND submission by the first quarter
Poster presentations highlighting results from Synta researchers and
Ganetespib resistance in KRAS mutant NSCLC is mediated through
bypassing the G2/M checkpoint and reactivating the PI3K/MTOR pathway
Sunday, April 19, 1:00 – 5:00 PM ET
Abstract number: 762
Chatterjee, et al.
Ganetespib sensitizes colorectal cancer in vitro and in vivo to a
clinically relevant regimen of radiation and chemotherapy
Tuesday, April 21, 8:00 AM – 12:00 PM PT
Abstract number: 3442
Nagaraju, et al.
STA-12-8666: a first-in-class HSP90 inhibitor drug conjugate (HDC)
designed to selectively deliver chemotherapy to tumors
Tuesday, April 21, 1:00 – 5:00 PM ET
Abstract number: 4409
Proia, et al.
Preclinical testing demonstrates strong activity of STA-12-8666, an
HSP90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)
Monday, April 20, 8:00 AM – 12:00 PM ET
Abstract number: 1731
Gapanova, et al.
Development of patient-derived platform to assess activity of
anticancer agents in pancreatic cancer
April 20, 8:00 AM – 12:00 PM ET
Abstract number: 1465
Khazak, et al.
Copies of these posters will be made available at www.syntapharma.com
in the Pipeline section under Ganetespib Presentations and STA-12-8666
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical
company focused on research, development and commercialization of novel
oncology medicines that have the potential to change the lives of cancer
patients. Synta’s lead oncology drug candidate, ganetespib, a novel heat
shock protein 90 (Hsp90) inhibitor, is currently being evaluated in
several clinical trials including the pivotal GALAXY-2 Phase 3 trial in
non-small cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor
Drug Conjugate (HDC) small molecule drug development program. IND
enabling studies have commenced for the first clinical candidate from
the HDC program, STA-12-8666, and preclinical evaluation of additional
HDC candidates is ongoing. For more information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements about Synta
Pharmaceuticals Corp. Such forward-looking statements can be identified
by the use of forward-looking terminology such as "will", "would",
"should", "expects", "anticipates", "intends", "plans", "believes",
"may", "estimates", "predicts", "projects", or similar expressions
intended to identify forward-looking statements. Such statements,
including statements related to Synta’s plan to file an IND for
STA-12-8666 by the first quarter of 2016, reflect Synta’s current views
with respect to future events and are based on assumptions and subject
to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements, including those described in "Risk Factors" of our Form 10-K
for the year ended December 31, 2014 as filed with the Securities and
Exchange Commission. Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future
events or otherwise, except as required by law.
Source: Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp.
Andrea Rabney, 212-600-1494
Eliza Schleifstein, 917-763-8106